18F-Facbc in Prostate Cancer : A Systematic Review and Meta-Analysis
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: "FACBC"/"fluciclovine" AND "prostate cancer"/"prostate" AND "PET"/"Positron Emission Tomography". Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Cancers - 11(2019), 9 vom: 11. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laudicella, Riccardo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
18F-FACBC |
|---|
| Anmerkungen: |
Date Revised 01.10.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers11091348 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301230390 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301230390 | ||
| 003 | DE-627 | ||
| 005 | 20231225104212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers11091348 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1004.xml |
| 035 | |a (DE-627)NLM301230390 | ||
| 035 | |a (NLM)31514479 | ||
| 035 | |a (PII)E1348 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laudicella, Riccardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18F-Facbc in Prostate Cancer |b A Systematic Review and Meta-Analysis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: "FACBC"/"fluciclovine" AND "prostate cancer"/"prostate" AND "PET"/"Positron Emission Tomography". Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 18F-FACBC | |
| 650 | 4 | |a PET/CT | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a recurrence | |
| 650 | 4 | |a review | |
| 700 | 1 | |a Albano, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Alongi, Pierpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Argiroffi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Bauckneht, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Baldari, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Bertagna, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Boero, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Vincentis, Giuseppe De |e verfasserin |4 aut | |
| 700 | 1 | |a Sole, Angelo Del |e verfasserin |4 aut | |
| 700 | 1 | |a Rubini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Fantechi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Frantellizzi, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Ganduscio, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Guglielmo, Priscilla |e verfasserin |4 aut | |
| 700 | 1 | |a Nappi, Anna Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Evangelista, Laura |e verfasserin |4 aut | |
| 700 | 0 | |a on the behalf of Young AIMN Working Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 11(2019), 9 vom: 11. Sept. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:9 |g day:11 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers11091348 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 9 |b 11 |c 09 | ||